“…Indeed, we have previously reported JQ1 to be highly effective in inhibiting the growth of GNAQ/GNA11 mutant UM cells associated with downregulation of DNA damage response genes, Bcl-xL and Rad51 (Ambrosini et al, 2015). A next-generation BET inhibitor, PLX51107 (Ozer et al, 2018;Plexxikon, Inc., Berkeley, CA), that has a half-life of 2.8 h and a broader therapeutic index, is currently being tested in clinical trials for patients with advanced malignancies including UM (NCT02683395). A next-generation BET inhibitor, PLX51107 (Ozer et al, 2018;Plexxikon, Inc., Berkeley, CA), that has a half-life of 2.8 h and a broader therapeutic index, is currently being tested in clinical trials for patients with advanced malignancies including UM (NCT02683395).…”